Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy

被引:1
作者
Jordi Bruna [1 ,2 ]
Roser Velasco [1 ,2 ]
机构
[1] Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO L'Hospitalet, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge)
[2] Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Autonoma de Barcelona, and Centro de Investigación Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)
关键词
oxaliplatin; chemotherapy-induced peripheral neuropathy; sigma-1; receptor; neurotoxicity; MR309; E-52862;
D O I
暂无
中图分类号
R730.53 [化学(药物)疗法]; R745 [周围神经及神经节疾病];
学科分类号
1002 ; 100214 ;
摘要
Chemotherapy-induced peripheral neuropathy is a very frequent neurological complication in cancer. Oxaliplatin(OXA) is a platinum analogue used as a first-line agent in the treatment of colorectal cancer. OXA induced peripheral neuropathy(OIN) is the main toxicity both during and after the completion of chemotherapy that presents as two distinct syndromes: acute and chronic neuropathy. None of the neuroprotective agents previously tested had prevented or limited the acute and/or chronic OIN. MR309(previously developed as E-52862) is a novel selective sigma-1 receptor(S1R) antagonist with preclinical analgesic activity in OXA-induced neuropathic pain in animal models. This review analyzes the results of the recently published phase Ⅱ, randomized, double-blind, placebo-controlled clinical trial including 124 patients with colorectal cancer(CRC) treated with MR309. This study shows encouraging findings in the setting of neuroprotection against OIN with an acceptable safety profile. The study demonstrated MR309 usefulness in decreasing acute OIN, by reducing cold hypersensitivity experienced by patients, and pointed to the amelioration of chronic OIN by lowering the proportion of patients who developed severe chronic OIN. In addition, we provide a summary and discussion on the pathways that can be modulated by the S1R to explain the observed clinical benefits in the OIN.
引用
收藏
页码:775 / 778
页数:4
相关论文
共 13 条
[1]   Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity [J].
Cavaletti, Guido ;
Marmiroli, Paola .
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (02) :113-121
[2]  
Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases[J] . Tzu-Yu Weng,Shang-Yi Anne Tsai,Tsung-Ping Su.Journal of Biomedical Science . 2017 (1)
[3]   Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration [J].
Pease-Raissi, Sarah E. ;
Pazyra-Murphy, Maria F. ;
Li, Yihang ;
Wachter, Franziska ;
Fukuda, Yusuke ;
Fenstermacher, Sara J. ;
Barclay, Lauren A. ;
Bird, Gregory H. ;
Walensky, Loren D. ;
Segal, Rosalind A. .
NEURON, 2017, 96 (02) :373-+
[4]   Molecular Mechanisms Involving Sigma-1 Receptor in Cell Apoptosis of BV-2 Microglial Cells Induced by Methamphetamine [J].
Shen, Kai ;
Zhang, Yuan ;
Lv, Xuan ;
Chen, Xufeng ;
Zhou, Rongbin ;
Nguyen, Lan K. ;
Wu, Xiaodong ;
Yao, Honghong .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2016, 15 (07) :857-865
[5]  
A role for sigma receptors in stimulant self-administration and addiction[J] . Jonathan L. Katz,Weimin C. Hong,Takato Hiranita,Tsung-Ping Su.Behavioural Pharmacology . 2016 (2 an)
[6]  
Long‐term course of oxaliplatin‐induced polyneuropathy: a prospective 2‐year follow‐up study[J] . Chiara Briani,Andreas A. Argyriou,Cristina Izquierdo,Roser Velasco,Marta Campagnolo,Paola Alberti,Barbara Frigeni,Mario Cacciavillani,Francesca Bergamo,Diego Cortinovis,Marina Cazzaniga,Jordi Bruna,Guido Cavaletti,Haralabos P. Kalofonos.J Peripher Nerv Syst . 2014 (4)
[7]  
Voltage‐gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin‐induced peripheral neurotoxicity: Results from a prospective multicenter study[J] . Andreas A. Argyriou,Guido Cavaletti,Anna Antonacopoulou,Armando A. Genazzani,Chiara Briani,Jordi Bruna,Salvatore Terrazzino,Roser Velasco,Paola Alberti,Marta Campagnolo,Sara Lonardi,Diego Cortinovis,Marina Cazzaniga,Cristina Santos,Aikaterini Psaromyalou,Aikaterini Angelopoulou,Haralabos P. Kalofonos.Cancer . 2013 (19
[8]  
Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry[J] . Floortje Mols,Tonneke Beijers,Valery Lemmens,Corina J. van den Hurk,Gerard Vreugdenhil,Lonneke V. van de Poll-Franse.Journal of Clinical Oncology . 2013 (21)
[9]  
Pharmacological properties of S1RA, a new sigma‐1 receptor antagonist that inhibits neuropathic pain and activity‐induced spinal sensitization[J] . L Romero,D Zamanillo,X Nadal,R Sánchez‐Arroyos,I Rivera‐Arconada,A Dordal,A Montero,A Muro,A Bura,C Segalés,M Laloya,E Hernández,E Portillo‐Salido,M Escriche,X Codony,G Encina,J Burgue?o,M Merlos,JM Baeyens,J Giraldo,JA López‐García,R Maldonado,CR Plata‐Salamán,JM Vela.British Journal of Pharmacology . 2012 (8)
[10]  
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update[J] . Andreas A. Argyriou,Jordi Bruna,Paola Marmiroli,Guido Cavaletti.Critical Reviews in Oncology / Hematology . 2011 (1)